New PET radiotracers for the imaging of neuroendocrine neoplasms

E Fortunati, G Argalia, L Zanoni, S Fanti… - … treatment options in …, 2022 - Springer
Opinion statement Neuroendocrine neoplasms (NEN) are a heterogeneous group of
tumours derived from cells of neuroendocrine origin and can potentially arise everywhere in …

Molecular imaging theranostics of neuroendocrine tumors

E Fortunati, N Bonazzi, L Zanoni, S Fanti… - Seminars in Nuclear …, 2023 - Elsevier
Neuroendocrine neoplasms (NEN) are rare and heterogeneous tumors, originating mostly
from the gastro-entero-pancreatic (GEP) tract followed by the lungs. Multidisciplinary …

Impact of 68Ga-FAPI-04 PET/CT on staging and therapeutic management in patients with digestive system tumors

A Kosmala, SE Serfling, W Schlötelburg… - Clinical Nuclear …, 2023 - journals.lww.com
Impact of 68Ga-FAPI-04 PET/CT on Staging and Therapeutic Man... : Clinical Nuclear Medicine
Impact of 68Ga-FAPI-04 PET/CT on Staging and Therapeutic Management in Patients With …

FAP imaging in rare cancer entities—first clinical experience in a broad spectrum of malignancies

K Dendl, R Finck, FL Giesel, C Kratochwil… - European journal of …, 2022 - Springer
Purpose 68 Ga-FAPI (fibroblast activation protein inhibitor) is a rapidly evolving and highly
promising radiotracer for PET/CT imaging, presenting excellent results in a variety of tumor …

FAPI PET/CT in the diagnosis of abdominal and pelvic tumors

T Yang, L Ma, H Hou, F Gao, W Tao - Frontiers in Oncology, 2022 - frontiersin.org
Positron emission tomography/computed tomography (PET/CT) with 18F-
fluorodeoxyglucose (18F-FDG) is currently a standard imaging examination used in clinical …

FAPI PET/CT research progress in digestive system tumours

D Peng, J He, H Liu, J Cao, Y Wang, Y Chen - Digestive and Liver Disease, 2022 - Elsevier
Abstract 18 F-fluorodeoxyglucose positron emission tomography/computed tomography has
been used in clinical practice for many years. This modality is of great value for tumour …

Detection of Bone Metastases by 68Ga‐DOTA‐SSAs and 18F‐FDG PET/CT: A Two‐Center Head‐to‐Head Study of Gastroenteropancreatic Neuroendocrine …

R Tian, Q Xie, F Yu, C Du, X Yao, S Zang… - Contrast Media & …, 2022 - Wiley Online Library
Purpose. This study aimed to assess the efficacy of dual‐tracer [68Ga‐DOTA‐somatostatin
receptor analogs (SSAs) and 18F‐fluorodeoxyglucose (FDG)] positron emission …

Current status and future prospects of PET-imaging applications in patients with gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs)

GZ Papadakis, AH Karantanas, K Marias… - European Journal of …, 2021 - Elsevier
Gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) represent a heterogeneous
group of rare neoplasms with increasing incidence over the last decades. Localization of …

68Ga-DOTA-FAPI-04 PET/CT in neuroendocrine carcinoma of the liver with elevated AFP level: comparison with: 18: F-FDG PET/CT

N Ergül, B Yılmaz, M Cin, TF Çermik - Clinical Nuclear Medicine, 2022 - journals.lww.com
A 68-year-old woman with a mass lesion in right hepatic lobe had an elevated α-fetoprotein
level (> 54,000 ng/mL). The lesion showed higher 68 Ga-DOTA-FAPI-04 uptake than 18 F …

Fibroblast activation protein inhibitor imaging and therapy in a patient with multiple endocrine neoplasia type 2A syndrome

S Barashki, G Divband, E Askari, H Amini… - Clinical Nuclear …, 2022 - journals.lww.com
A patient with multiple endocrine neoplasia type 2A syndrome who had exhausted several
surgeries and radiotherapy was referred to nuclear medicine department for theranostic …